Home » Stocks » CANF

Can-Fite BioPharma Ltd. (CANF)

Stock Price: $2.18 USD 0.02 (0.93%)
Updated Jul 26, 2021 9:41 AM EDT - Market open
Market Cap 38.44M
Revenue (ttm) 763,000
Net Income (ttm) -14.44M
Shares Out 17.19M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $2.18
Previous Close $2.16
Change ($) 0.02
Change (%) 0.93%
Day's Open 2.18
Day's Range 2.16 - 2.18
Day's Volume 33,595
52-Week Range 1.51 - 4.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study

2 weeks ago - Business Wire

Can-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to develop Piclidenoson to treat osteoarthritis in c...

4 weeks ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets

4 weeks ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...

1 month ago - Business Wire

Nonalcoholic steatohepatitis (NASH) is the leading cause of disease leading to liver transplants among women and the second-leading cause for liver transplants overall. In addition, NASH is expected to ...

1 month ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...

1 month ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021

1 month ago - Business Wire

by Mark Gilman Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), an Israeli-based biotechnology company advancing a pipeline of proprietary small-molecule drugs that address inflammatory, cancer and li...

1 month ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update

1 month ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

1 month ago - Business Wire

Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced the co...

2 months ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021

2 months ago - Business Wire

Can-Fite BioPharma Ltd (NYSE: CANF) has expanded its Phase 2 COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized, double-blind, placebo-controlled study evalua...

3 months ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...

3 months ago - Business Wire

Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for its drug candidates Piclidenoson and Namodeno...

3 months ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...

3 months ago - Business Wire

PAC, CANF, GOL, HRTH, and INLX have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2021

Other stocks mentioned: GOL, HRTH, INLX, PAC
3 months ago - Zacks Investment Research

Can-Fite BioPharma (NYSE: CANF) has completed pre-clinical studies demonstrating that a Cannabidiol (CBD)-rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth. The company's lead...

3 months ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

3 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...

3 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports 2020 Financial Results & Provides Clinical Development Update

4 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

4 months ago - Business Wire

Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday.

Other stocks mentioned: ACIU, MRNA
4 months ago - Benzinga

Can-Fite Biopharma (CANF) stock is on the rise Tuesday after announcing a $42.7 million distribution rights deal with Ewopharma. The post CANF Stock: Why Are Can-Fite Biopharma Shares Skyrocketing Today?

4 months ago - InvestorPlace

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma

4 months ago - Business Wire

CanFite Biopharma Ltd (CANF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 months ago - Zacks Investment Research

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Enrolls First Patient in Phase II COVID-19 Study Under FDA Protocol

4 months ago - Business Wire

Can-Fite BioPharma (NYSE: CANF) reports new data from Phase 2 trial evaluating namodenoson in advanced liver cancer, including the overall survival of nearly four years in two patients under treatment. ...

5 months ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, c...

5 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Announces Inhibition of Liver Fibrosis by Cannabis Compounds in Preclinical Studies

5 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammato...

5 months ago - Business Wire

Can-Fite Biopharma  Ltd. was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020.

6 months ago - Benzinga

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Announces Publication of Namodenoson Liver Cancer Study in Peer Reviewed Journal—Cancers

6 months ago - Business Wire

Petach Tikva, Israel--(Newsfile Corp. - January 4, 2021) - Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...

6 months ago - Newsfile Corp

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammato...

7 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports on Progress with its Namodenoson NASH Program

7 months ago - Business Wire

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update

7 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Namodenoson Abstract Selected as ‘Best of The Liver Meeting ‘ in the NASH Category of the American Association of Liver Diseases (AASLD)

8 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET

8 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of AASLD Conference

8 months ago - Business Wire

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Pe...

Other stocks mentioned: FPRX, GTBP, IFRX, TNXP, VTVT, VXRT
8 months ago - InvestorPlace

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020

8 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020

9 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammato...

9 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Selected to Deliver Late-Breaking Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases

9 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Participate in Two BioPharma Partnering Conferences

10 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

10 months ago - Business Wire

PETACH TIKVA, Israel--(BUSINESS WIRE)--FDA Clears Can-Fite to Commence Phase II COVID-19 Study

10 months ago - Business Wire

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

About CANF

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial f... [Read more...]

Industry
Biotechnology
Founded
1994
CEO
Pnina Fishman
Employees
8
Stock Exchange
NYSEAMERICAN
Ticker Symbol
CANF
Full Company Profile

Financial Performance

In 2020, CANF's revenue was 763,000, a decrease of -62.45% compared to the previous year's 2.03 million. Losses were -14.44 million, 14.4% more than in 2019.

Financial numbers in millions ILS.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for CANF stock is "Buy" and the 12-month stock price forecast is 6.00.

Price Target
$6.00
Analyst Consensus: Buy